Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Esterline Technologies Corporation (ESL): Insiders Are Buying This Defense Stock, But Should You?

Page 1 of 2

Esterline Technologies Corporation (NYSE:ESL) is a leading world-wide supplier to the aerospace and defense industry, specializing in three core areas: Avionics & Controls, Sensors & Systems, and Advanced Materials. Recent significant insider buying has been reported at the company. Should investors follow the insiders and buy the stock?

Valuation

With regards to valuation, Esterline trades at a P/E of 19.51, close to the industry average. Its price-to-earnings ratio is lower than that of competitors like AMETEK, Inc. (NYSE:AME), but higher than that of others like Lockheed Martin Corporation (NYSE:LMT). The situation is similar when taking into account future earning estimates:
Esterline Technologies Corporation (NYSE:ESL)’s forward P/E is 11.59, sitting halfway between AMETEK’s 17.40, and Lockheed’s 10.67. However, the situation is different when one looks at the stock’s PEG and P/B: Esterline beats its competitors in both ratios (the stock is trading at a P/B of 1.34 and a PEG of 1.30). All in all, Esterline is neither overvalued nor undervalued when taking into account price-to-earning ratios (both current and forward), but, relative to its peers and industry, the stock does seem to be slightly undervalued when taking into account its price-to-book and P/E-to-growth (PEG) ratios.

Analysts

Wall Street analysts are slightly bullish on the stock: it currently has an average recommendation of 2.20 (overweight-hold) and an average price target of $76.89, which implies 7.7% upside potential from current prices. However, AMETEK, Inc. (NYSE:AME) seems to be the most favored by analysts, as it has an average recommendation of 1.90 (buy-overweight), and a price target that implies more than a 13% upside potential. With regards to Lockheed Martin Corporation (NYSE:LMT), even though it beat most of the industry’s stocks in the P/E arena, analysts are mostly neutral on this one: the stock has a 2.80 average recommendation, and its average price target is actually lower than the current stock price.

P/E Fw P/E P/B PEG Avg Rec Avg PT (%implied upside) Div Yield
ESL 19.51 11.59 1.34 1.30 2.20 $76.89 (+7.7%) N/A
AME 21.38 17.40 3.86 1.52 1.90 $45.56 (+13.33%) 0.60%
LMT 11.50 10.67 802 1.59 2.80 $95.67 (-0.63%) 4.78%
Edge LMT LMT ESL ESL AME AME LMT

Price movements

Despite defense spending reduction fears, Esterline Technologies Corporation (NYSE:ESL) has had a good run YTD, as the stock has gained roughly 12.5%. Its price has dropped from its 52-week high attained in mid-March (it is currently 8.36% off its high of $77.90), but it is almost 40% above its 52-week lows of $51.13. The stock is also trading close to its all-time high of $80.57 (July 2011) and far from its low of $19.76, which was reached in March 2009 amid the financial crisis.

Insider buying

On April 11, Director Henry Ward Winship IV bought 18,500 shares of Esterline Technologies in the open market, at an average price of $75.56. That is a purchase of almost $1.4 million. The next day, he bought 9,500 more shares, at an average price of $75.12, spending more than $700,000. So in just two days, Mr. Winship, a director with unique insight into the company’s business, invested $2,111,500 of his own money to buy Esterline Technologies Corporation (NYSE:ESL) shares in the open market. This is significant insider buying, and is therefore a bullish sign for the stock.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!